<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619433</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-324</org_study_id>
    <nct_id>NCT04619433</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination&#xD;
      with Famitinib plus chemotherapy in subjects with NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of Camrelizumab in&#xD;
      combination with Famitinib plus chemotherapy in subjects with NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1210 in combination with Famitinib plus chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1：Serum concentrations of Camrelizumab</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Plasma concentrations of Famitinib</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Area Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib.</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Maximum Concentration (Cmax) of Famitinib.</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Time to Maximum Concentration (Tmax) of Famitinib.</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Half-life (t1/2 z) of Famitinib.</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Apparent Clearance (CL/F) of Famitinib</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days）</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1：Vz/F of Famitinib.</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1.</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1:Objective Response Rate (ORR) as Assessed by investigators</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:Duration of Response (DOR) as Assessed by investigators</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:Progression-free Survival (PFS) as Assessed by investigators</measure>
    <time_frame>Cycle 2; each cycle is 21 days (up to 42 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1:Overall Survival (OS).</measure>
    <time_frame>Up to approximately 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Overall Survival (OS)</measure>
    <time_frame>Up to approximately 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Progression-free Survival (PFS) as Assessed by investigators according to RECIST 1.1.</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Objective Response Rate (ORR) as Assessed by investigators and BICR according to RECIST 1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Duration of Response (DOR) as Assessed by investigators and BICR according to RECIST 1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Disease Control Rate(DCR) as Assessed by investigators and BICR according to RECIST 1.1</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2:Number of Participants With Adverse Events and Serious Adverse Event as Assessed by CTCAE v5.0.</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Non-squamous Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab;Pemetrexed and Carboplatin; Famitinib;</intervention_name>
    <description>Part 1:&#xD;
Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib&#xD;
Part 2:&#xD;
Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib</description>
    <arm_group_label>Treatment group A</arm_group_label>
    <other_name>SHR1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab;Pemetrexed and Carboplatin;Placebo</intervention_name>
    <description>Part 2:&#xD;
Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo</description>
    <arm_group_label>Treatment group B</arm_group_label>
    <other_name>SHR1210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form, male or female, 18-70 years of age.&#xD;
&#xD;
          2. Histologically or cytologically confirmed, Stage IIIB-IV non-squamous NSCLC&#xD;
&#xD;
          3. EGFR mutation and ALK rearrangement status must be negative.&#xD;
&#xD;
          4. No prior system chemotherapy for advanced/metastatic NSCLC.&#xD;
&#xD;
          5. Measurable diseaseas defined by RECIST v1.1.&#xD;
&#xD;
          6. ECOG performance status of 0 or 1.&#xD;
&#xD;
          7. Has a life expectancy of at least 3 months.&#xD;
&#xD;
          8. Adequater organ function.&#xD;
&#xD;
          9. Female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             within 7 days prior to the first dose, and be willing to use a recognized effective&#xD;
             contraceptive measure during the study and within 3 months after the last dose of the&#xD;
             study drug; Male subjects with partners of childbearing potential must either be&#xD;
             surgically sterilized or agree to take effective contraceptive measures during the&#xD;
             study and within 3 months after the last dose of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1、 Cancer-Specific Exclusions&#xD;
&#xD;
          1. Other histological types of non-small cell lung cancer.&#xD;
&#xD;
          2. Subjects with carcinomatous meningitis and spinal cord compression.&#xD;
&#xD;
          3. Subjects with untreated central nervous system (CNS) metastasis.&#xD;
&#xD;
          4. Subjects who can be treated with surgical resection or radical radiotherapy.&#xD;
&#xD;
          5. Subjects who previously received anti-PD-1(L1) or CTLA4 monoclonal antibody, VEGF or&#xD;
             VEGFR signaling pathway single target/multiple target inhibitor or monoclonal&#xD;
             antibodies.&#xD;
&#xD;
        2. Medical history and complications&#xD;
&#xD;
          1. Subjects with any active, known, or suspected autoimmune diseases.&#xD;
&#xD;
          2. Subjects who require systemic corticosteroids prednisone (&gt; 10 mg/day or equivalent)&#xD;
             or other immunosuppressants within 14 days prior to the first dose.&#xD;
&#xD;
          3. Subjects who received cancer vaccines or other immunostimulatory anti-cancer agents&#xD;
             (interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to&#xD;
             the first dose.&#xD;
&#xD;
          4. Subjects who received anti-cancer TCM within 14 days prior to the first dose.&#xD;
&#xD;
          5. Subjects who are in another clinical study or last participated (last dose) in a&#xD;
             clinical study less than 4 weeks (or 5 half-lives of the study drug) from the first&#xD;
             dose, whichever is shorter.&#xD;
&#xD;
          6. Subjects who are expected to require other forms of anti-cancer treatment during the&#xD;
             study.&#xD;
&#xD;
          7. Subjects who received major surgery within 4 weeks prior to the first dose,&#xD;
             non-thoracic radiation therapy &gt; 30 Gy within 4 weeks prior to the first dose,&#xD;
             thoracic radiation therapy &gt; 30 Gy within 24 weeks prior to the first dose, or&#xD;
             palliative radiation ≤ 30 Gy within 2 weeks prior to the first dose, and failed to&#xD;
             recover from the toxicities and/or complications of these interventions to NCI-CTC AE&#xD;
             Grade ≤ 1 (except for alopecia and fatigue). Palliative radiotherapy for symptomatic&#xD;
             control is permitted, but must be completed within 2 weeks prior to starting the study&#xD;
             treatment.&#xD;
&#xD;
          8. Subjects highly suspected of interstitial lung disease, or with conditions that may&#xD;
             interfere with the testing or management of suspected treatment-related pulmonary&#xD;
             toxicities, or other moderate to severe lung diseases that seriously affect pulmonary&#xD;
             function.&#xD;
&#xD;
          9. Subjects with a history of malignant tumors.&#xD;
&#xD;
         10. Subjects with severe cardiovascular disease.&#xD;
&#xD;
         11. Subjectss with hypertension which cannot be well controlled by antihypertensives.&#xD;
&#xD;
         12. Subjects with clinically significant hemorrhage or clear bleeding tendency within 3&#xD;
             month prior to the first dose.&#xD;
&#xD;
         13. Events of arterial/venous thrombosis within 6 months prior to the first dose.&#xD;
&#xD;
         14. Subjects who require long-term anticoagulant therapy with warfarin or heparin.&#xD;
&#xD;
         15. Subjects who require long-term antiplatelet therapy.&#xD;
&#xD;
         16. Significant vascular invasions or a high possibility of significant vascular invasions&#xD;
             that may cause bleeding as determined by the investigator during treatment.&#xD;
&#xD;
         17. Subjects with active pulmonary tuberculosis (TB).&#xD;
&#xD;
         18. Subjects with serious infection within 4 weeks prior to the first dose, including but&#xD;
             not limited to infective complications, bacteremia, and severe pneumonia that require&#xD;
             hospitalization.&#xD;
&#xD;
         19. Subjects who prepare to receive or have previously received tissue/organ transplants.&#xD;
&#xD;
         20. Gastrointestinal disorder or surgical history that may affect the swallowing,&#xD;
             digestion, and absorption of the oral drug as determined by the investigator.&#xD;
&#xD;
         21. Subjects who plan to receive or have received live vaccines within 30 days prior to&#xD;
             the first dose.&#xD;
&#xD;
         22. Subjects with uncontrolled cancer pain.&#xD;
&#xD;
        3. Physical examination and laboratory tests&#xD;
&#xD;
          1. Known history of human immunodeficiency virus (HIV) seropositive status or acquired&#xD;
             immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          2. Active hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          3. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
             requiring repeated drainage.&#xD;
&#xD;
        4. Allergies and adverse drug reactions&#xD;
&#xD;
          1. Severe allergic reactions to other monoclonal antibodies.&#xD;
&#xD;
          2. Allergy or intolerance during an infusion.&#xD;
&#xD;
          3. History of severe allergies to pemetrexed, carboplatin, or their premedications.&#xD;
&#xD;
        5. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or&#xD;
        substance abuse.&#xD;
&#xD;
        6. Based on the investigator's judgment, subjects with a history or current evidence of&#xD;
        diseases, treatments, or laboratory abnormalities that may affect study results, interfere&#xD;
        with study procedures, or are not in the best interests of the subjects, should be&#xD;
        excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hosipital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Zhao, Doctor</last_name>
      <phone>+86-10-01088196393</phone>
      <email>ohjerry@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hosipital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Fang, Doctor</last_name>
      <phone>+86-10-01088196393</phone>
      <email>fangjian5555@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanqiu Zhao, Doctor</last_name>
      <phone>+86-0371-65587418</phone>
      <email>13938252350@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospita</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng Hu, Doctor</last_name>
      <phone>+86-27-87670003</phone>
      <email>ehusmn@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospita of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caigang Liu, Doctor</last_name>
      <phone>+86-18940254967</phone>
      <email>liucg@sj-hospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Lung Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou, Doctor</last_name>
      <phone>+86-21-65115006</phone>
      <email>caicunzhoudr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongsheng Wang, Doctor</last_name>
      <phone>+86-18980602258</phone>
      <email>wangys75@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiubao Ren, Doctor</last_name>
      <phone>+86-18622221235</phone>
      <email>rwziyi@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

